Immunogenicity and Reactogenicity of the Beta-variant Recombinant Protein Booster Vaccine (VidPrevtyn Beta, Sanofi) Compared to a Bivalent mRNA Vaccine (Comirnaty Original/Omicron BA.4-5, BioNTech-Pfizer) in Adults Previously Vaccinated With at Least 3 Doses of COVID-19 mRNA Vaccine
Clinical trial NCT05749926 · UNKNOWN
Trial details
- NCT number
- NCT05749926
- Sponsor
- Assistance Publique - Hôpitaux de Paris
- Status
- UNKNOWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-05-16
- Primary completion
- 2023-07-12
- Enrollment
- 248
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.